Ligand Pharmaceuticals Inc (LGND)
Stock-Based Compensation
$53.27M
TTM · Period ending: · USD
LGND Stock-Based Compensation
Latest reported$53.27Mperiod ending
Latest reported$53.27Mperiod ending
LGND TTM Stock-Based Comp ($0.00 → $53.27M)
TTM stock-based compensation
High-resolution chart · PNG
LGND stock-based compensation history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 53,265,000 | |
| 39,612,000 | |
| 29,016,000 | |
| 22,270,000 | |
| 33,755,000 | |
| 44,815,000 | |
| 52,149,000 | |
| 44,625,000 | |
| 25,278,000 | |
| 21,425,000 | |
| 14,091,000 | |
| 14,091,000 | |
| 19,804,000 | |
| 12,597,000 | |
| 12,597,000 | |
| 12,597,000 | |
| 0 | |
| 0 | |
| 8,405,000 | |
| 18,380,000 | |
| 26,120,000 | |
| 33,479,000 | |
| 30,727,000 | |
| 27,052,000 | |
| 25,609,000 | |
| 24,821,000 | |
| 24,515,000 | |
| 24,224,000 | |
| 23,397,000 | |
| 21,638,000 | |
| 20,846,000 | |
| 23,835,000 | |
| 23,613,000 | |
| 23,425,000 | |
| 24,915,000 | |
| 21,120,000 | |
| 20,796,000 | |
| 20,820,000 | |
| 18,893,000 | |
| 16,637,000 | |
| 14,549,000 | |
| 13,662,000 | |
| 12,458,000 | |
| 11,986,000 | |
| 12,852,000 | |
| 12,117,000 | |
| 11,270,000 | |
| 10,312,000 | |
| 8,143,000 | |
| 6,609,000 | |
| 5,666,000 | |
| 5,100,000 | |
| 4,580,000 | |
| 4,482,000 | |
| 4,067,000 | |
| 3,821,000 | |
| 3,758,000 | |
| 3,608,000 | |
| 3,351,000 | |
| 2,957,000 | |
| 2,564,000 | |
| 2,153,000 | |
| 2,325,000 | |
| 2,938,000 | |
| 3,122,000 | |
| 3,169,000 | |
| 3,365,000 | |
| 6,048,000 | |
| 5,307,000 | |
| 4,427,000 | |
| 4,603,000 | |
| 8,576,000 | |
| 8,576,000 | |
| 8,576,000 | |
| 13,134,000 | |
| 10,892,000 | |
| 10,892,000 | |
| 10,892,000 | |
| 6,152,000 | |
| 814,000 | |
| 814,000 | |
| 814,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |